InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients

Kurinami N et al.
Used Parameters : FM, PBF

Publication Year : 2018

Country : Japan

Journal : Diabetes Research and Clinical Practice

Aims We examined dapagliflozin-induced changes in liver fat accumulation. Methods We prospectively recruited Japanese patients with inadequately controlled type 2 diabetes mellitus (T2DM)[hemoglobin A1c (HbA1c)> 7.0%]. Dapagliflozin (5 mg/day) or non-sodium glucose cotransporter 2 inhibitors (SGLT2i) was added to the patients' treatment regimen for 6 months. Changes in liver fat accumulation were assessed by the liver-to-spleen (L/S) attenuation ratio using abdominal computed tomography (CT). Results This study enrolled …
Full text